We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Norvasc Patent Still Invalid: Court

Law360 (May 21, 2007, 12:00 AM EDT) -- An appeals court refused Monday to rehear Pfizer Inc.’s case against Apotex Inc., giving the Canadian generics-maker the green light to launch a generic form of Pfizer’s blockbuster blood-pressure drug Norvasc.

The U.S. Court of Appeals for the Federal Circuit denied Pfizer’s request for an en banc rehearing and left intact its previous ruling that found the pharmaceutical behemoth’s patent for Norvasc unenforceable. In so doing, the court granted Apotex’ request that it expedite its issuance of the decision.

The court’s previous ruling, handed down March...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.